- Conditions
- Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Interventions
- Tasquinimod, Radium 223
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Laboratory Biomarker Analysis, Sipuleucel-T, Tasquinimod
- Other · Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Prostate Cancer
- Interventions
- tasquinimod, Placebo
- Drug
- Lead sponsor
- Active Biotech AB
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 34
- States / cities
- Tucson, Arizona • Oxnard, California • Santa Monica, California + 31 more
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
- Interventions
- Ruxolitinib, Tasquinimod
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- tasquinimod, tasquinimod 0.25 mg; 0.5 mg, tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
- Drug
- Lead sponsor
- Andrew J. Armstrong, MD
- Other
- Eligibility
- 18 Years to 79 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Durham, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Tasquinimod, IRd chemotherapy
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- ABR-215050, tasquinimod, Placebo
- Drug
- Lead sponsor
- Active Biotech AB
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 54
- States / cities
- Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 43 more